businesspress24.com - AVI BioPharma to Present Company Overview at the Lazard Capital Markets 8th Annual Healthcare Confer
 

AVI BioPharma to Present Company Overview at the Lazard Capital Markets 8th Annual Healthcare Conference

ID: 1054440

Webcast Accessible via AVI Website

(firmenpresse) - BOTHELL, WA -- (Marketwire) -- 11/08/11 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the Company is scheduled to present at the Lazard Capital Markets 8th Annual Healthcare Conference in New York, NY, on Tuesday, November 15, at 2:00 p.m. Eastern Time. Chris Garabedian, AVI's President and CEO, will provide a company overview.

The presentation will be webcast live under the events section of AVI's website at and will be archived there following the presentation for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.



AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious disease. For more information, please visit .



AVI Media and Investor Contact:
Erin Cox
Manager, Corporate Communications and Investor Relations
425.354.5140


AVI Media Contact:
David Schull
Russo Partners
212.845.4271




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Rapid Micro Biosystems Announces Biomedical Advanced Research and Development Authority (BARDA) Exercises Second Year Option Under Three-Year Contract
Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 08.11.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 1054440
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

BOTHELL, WA


Phone:

Kategorie:

Trials


Anmerkungen:


Diese Pressemitteilung wurde bisher 190 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"AVI BioPharma to Present Company Overview at the Lazard Capital Markets 8th Annual Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von

AVI BioPharma, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von AVI BioPharma, Inc.



 

Who is online

All members: 10 562
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 63


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.